Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM
BLU-285-2405 is a multi-center, synthetic control, observational and retrospective study
 designed to compare clinical outcomes for avapritinib compared with best available therapy
 for patients with AdvSM.
Inclusion Criteria for Patients in the External Control Arm:

 1. Diagnosed with AdvSM, with known subtype including SM-AHN, ASM, or MCL

 2. Received at least one line of systemic therapy for AdvSM, which may include but not
 limited to regimens containing:

 Midostaurin Cytoreductive therapy: cladribine, interferon alpha, azacitidine,
 decitabine Selective TKIs: imatinib, nilotinib, dasatinib Hydroxyurea Antibody
 therapy: brentuximab vedotin

 3. Adult (≥18 years of age) at the initiation of first systemic line of therapy at the
 participating site

 4. Had available performance status (e.g., ECOG score or Karnofsky score)

 5. Had an index date at least 3 months prior to the start of data collection (in order to
 include patients with at least 3 months of follow-up after index date), unless date of
 death occurred less than three months from index date

 6. Had an approved waiver of informed consent or signed informed consent for
 participation in the retrospective chart review study, if no institutional waiver from
 the site was granted

 Exclusion Criteria for Patients in the External Control Arm

 1. Malignancy that is not in remission at time of SM diagnosis, or new non-hematological
 malignancy diagnosed after SM diagnosis, except for: completely resected basal cell
 and squamous cell skin cancer, curatively treated localized prostate cancer, and
 completely resected carcinoma in situ of any site

 2. Among patients with SM-AHN, presence of either of the following:

 -  Patients in whom the SM component is consistent with an indolent systemic
 mastocytosis (ISM) or SSM or,

 -  the AHN component is a lymphoid malignancy, or one of the following myeloid
 malignancies: acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) that
 is very high-or high-risk as defined by the IPSS-R, or a Philadelphia chromosome
 positive malignancy or,

 -  there is a known FIP1L1/PDGFRA fusion gene (including those with CHIC-2 deletion
 and partial deletion of PDGFRA), independent of KIT mutational status

 3. Received avapritinib as the first line of systemic therapy for AdvSM at participating
 site, or prior to initiation of first systemic therapy at participating site.